103 related articles for article (PubMed ID: 22230651)
21. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
de Haan L; Booij J; Lavalaye J; van Amelsvoort T; Linszen D
Psychopharmacology (Berl); 2006 Jan; 183(4):500-5. PubMed ID: 16292589
[TBL] [Abstract][Full Text] [Related]
22. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study.
Lataster J; van Os J; de Haan L; Thewissen V; Bak M; Lataster T; Lardinois M; Delespaul PA; Myin-Germeys I
J Clin Psychiatry; 2011 Oct; 72(10):1397-404. PubMed ID: 21208588
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
24. D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients.
Regenthal R; Kunstler U; Hesse S; Sabri O; Preiss R
Int J Clin Pharmacol Ther; 2005 Aug; 43(8):370-8. PubMed ID: 16119512
[TBL] [Abstract][Full Text] [Related]
25. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
[TBL] [Abstract][Full Text] [Related]
26. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
[TBL] [Abstract][Full Text] [Related]
27. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia.
Uchida H; Rajji TK; Mulsant BH; Kapur S; Pollock BG; Graff-Guerrero A; Menon M; Mamo DC
J Clin Psychopharmacol; 2009 Dec; 29(6):571-5. PubMed ID: 19910723
[TBL] [Abstract][Full Text] [Related]
28. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
29. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
[TBL] [Abstract][Full Text] [Related]
30. Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics.
Uchida H; Graff-Guerrero A; Mulsant BH; Pollock BG; Mamo DC
Schizophr Res; 2009 Apr; 109(1-3):130-3. PubMed ID: 19179049
[TBL] [Abstract][Full Text] [Related]
31. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
Catafau AM; Corripio I; Pérez V; Martin JC; Schotte A; Carrió I; Alvarez E
Psychiatry Res; 2006 Dec; 148(2-3):175-83. PubMed ID: 17059881
[TBL] [Abstract][Full Text] [Related]
32. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
Mamo D; Kapur S; Keshavan M; Laruelle M; Taylor CC; Kothare PA; Barsoum P; McDonnell D
Neuropsychopharmacology; 2008 Jan; 33(2):298-304. PubMed ID: 17443131
[TBL] [Abstract][Full Text] [Related]
33. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
[TBL] [Abstract][Full Text] [Related]
34. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine.
Machielsen M; Beduin AS; Dekker N; ; Kahn RS; Linszen DH; van Os J; Wiersma D; Bruggeman R; Cahn W; de Haan L; Krabbendam L; Myin-Germeys I
J Psychopharmacol; 2012 Jan; 26(1):189-95. PubMed ID: 21768161
[TBL] [Abstract][Full Text] [Related]
35. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia.
Yasui-Furukori N; Saito M; Nakagami T; Sugawara N; Sato Y; Tsuchimine S; Furukori H; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Apr; 34(3):537-40. PubMed ID: 20170699
[TBL] [Abstract][Full Text] [Related]
36. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
Takano A; Suhara T; Ikoma Y; Yasuno F; Maeda J; Ichimiya T; Sudo Y; Inoue M; Okubo Y
Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
[TBL] [Abstract][Full Text] [Related]
37. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
[TBL] [Abstract][Full Text] [Related]
39. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.
Mamo D; Kapur S; Shammi CM; Papatheodorou G; Mann S; Therrien F; Remington G
Am J Psychiatry; 2004 May; 161(5):818-25. PubMed ID: 15121646
[TBL] [Abstract][Full Text] [Related]
40. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
